Standard BioTools Inc. Defined Contribution Plan, Employer Matching Contribution, Percent of Match
Standard BioTools Inc. (LAB) reported Defined Contribution Plan, Employer Matching Contribution, Percent of Match of 100.00% for the 12-month period ending 2019-12-31, per its 10-K filed 2024-03-01.
Discontinued › Notes › Compensation Related Costs
us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch · last filed 2024-03-01
- Standard BioTools Inc. defined contribution plan, employer matching contribution, percent of match for fiscal 2019 was 100.00%.
- Standard BioTools Inc. defined contribution plan, employer matching contribution, percent of match for fiscal 2017 was 100.00%, a 0.00% change from fiscal 2016.
- Standard BioTools Inc. defined contribution plan, employer matching contribution, percent of match for fiscal 2016 was 100.00%, a 0.00% change from fiscal 2015.
- Standard BioTools Inc. defined contribution plan, employer matching contribution, percent of match for fiscal 2015 was 100.00%.
| Period end | Defined Contribution Plan, Employer Matching Contribution, Percent of Match 12 month |
|---|---|
| 2019-12-31 | 100.00% 10-K · filed 2024-03-01 |
| 2017-12-31 | 100.00% 10-K · filed 2019-03-18 |
| 2016-12-31 | 100.00% 10-K · filed 2018-03-08 |
| 2015-12-31 | 100.00% 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |